Zolmitriptan nasal spray

A technology of zolmitriptan and nasal spray, which is applied in the field of zolmitriptan nasal spray, can solve the problems of drug overdose, multiple economic burdens for patients, and high price, and achieve the prevention of drug overdose and drug abuse, The effect of reducing the requirements of filling equipment and mature processing technology
CN103285476AInactive Publication Date: 2013-09-11北京天衡药物研究院有限公司
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
北京天衡药物研究院有限公司
Publication Date
2013-09-11
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a zolmitriptan nasal spray which comprises a spray bottle and a spray head and is characterized in that the spray bottle comprises a casing (1) and a liner (2) with the volume of 1.2 ml; the liner shape of the spray bottle is in a shape of a cylinder, the combination of a cylinder and a cylinder plus cone, or the combination of a cylinder plus, a cone and a plug cylinder with a smaller diameter; the casing of the spray bottle has the same shape, size and interface parts with the conventional 10-ml spray device sold in the market; and the spray head adopts the spray head of the conventional 10-ml spray device sold in the market. The zolmitriptan nasal spray has the advantages of few residues, high safety, many effective liquid spraying times, can reduce the production cost, and eliminate medicine waste.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field:

[0001] The invention relates to a zolmitriptan nasal spray, in particular to a zolmitriptan nasal spray using a spray bottle with a volume of 1.2ml. Background technique:

[0002] Zolmitriptan is a second-generation triptan drug, which is a highly selective and potent 5-HT1B / 1D receptor agonist, which stimulates intracranial blood vessels (including arteriovenous anastomosis) and trigeminal nervous system The 5-HT1B / 1D receptors of sensory nerves can constrict intracranial arteries and inhibit the release of neuropeptides after inflammation, thereby alleviating the onset of migraine. It is currently one of the most ideal drugs for treating migraine.

[0003] Zolmitriptan was first marketed abroad (1997) in the form of tablets, the original manufacturer: AstraZeneca, specifications: 2.5mg, 5mg, trade name: Zomig. Advantages of the tablet: the curative effect is clear, and 73% of the patients' migraine can be relieved after 4 hours of administration. Disadva...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More